Elicio Therapeutics (ELTX) Cash from Financing Activities (2020 - 2026)

Elicio Therapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at $8.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 22.28% year-over-year to $8.0 million; the trailing twelve-month figure through Mar 2026 stood at $34.4 million (down 17.37% YoY), and the FY2025 full-year result was $36.7 million, down 13.29% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $8.0 million, up from $4.9 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $30.8 million in Q3 2024, with the low at -$14000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $8.6 million across 5 years, with a median of $8.8 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 100.01% — and 2023, when it jumped 71814.29%.
• Elicio Therapeutics' Cash from Financing Activities stood at $11.2 million in 2022, then tumbled by 37.36% to $7.0 million in 2023, then sank by 96.76% to $227000.0 in 2024, then jumped by 2042.29% to $4.9 million in 2025, then soared by 65.06% to $8.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $8.0 million (Q1 2026), $4.9 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.